Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2023 | MP0533, a CD3-engaging DARPin, in R/R AML or MDS/AML: preliminary results of a Phase I/IIa trial

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, introduces a Phase I/IIa study (NCT05673057) of MP0533, a CD3-engaging DARPin (Designed Ankyrin Repeat Protein) which targets CD33, CD123, and CD70 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Honoraria: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Pfizer, Takeda, Ichnos Sciences, AvenCell, Incyte Biosciences, Molecular Partners, AbbVie, Autolus, advesya (CanCell Therapeutics), Genmab US, Interius BioTherapeutics, Nektar Therapeutics, Orbital Therapeutics, Sanofi, Scare
Research Funding: Janssen, Roche, BMS/Celgene: Amgen, Miltenyi Biotec, Novartis, Gilead/Kite, Seagen, Takeda, Molecular Partners
Speakers Bureau: Janssen, Roche, BMS/Celgene, Novartis, Gilead/Kite, Pfizer, AstraZeneca, GSK, LAWG, Springer Healthcare
Travel Support: Roche, Gilead/Kite, Pfizer